Literature DB >> 33030502

Appropriate Analysis of Duration of Response Data in Cancer Trials.

Zachary R McCaw1, Lu Tian2, Lee-Jen Wei3.   

Abstract

Entities:  

Mesh：

Year:  2020        PMID： 33030502      PMCID： PMC8687453          DOI： 10.1001/jamaoncol.2020.4657

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  3 in total

1.  Evaluating Treatment Effect Based on Duration of Response for a Comparative Oncology Study.

Authors:  Bo Huang; Lu Tian; Enayet Talukder; Mace Rothenberg; Dae Hyun Kim; Lee-Jen Wei
Journal:  JAMA Oncol       Date:  2018-06-01       Impact factor: 31.777

2.  Results From the CheckMate 143 Clinical Trial: Stalemate or New Game Strategy for Glioblastoma Immunotherapy?

Authors:  Yagmur Muftuoglu; Linda M Liau
Journal:  JAMA Oncol       Date:  2020-07-01       Impact factor: 31.777

3.  Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.

Authors:  David A Reardon; Alba A Brandes; Antonio Omuro; Paul Mulholland; Michael Lim; Antje Wick; Joachim Baehring; Manmeet S Ahluwalia; Patrick Roth; Oliver Bähr; Surasak Phuphanich; Juan Manuel Sepulveda; Paul De Souza; Solmaz Sahebjam; Michael Carleton; Kay Tatsuoka; Corina Taitt; Ricardo Zwirtes; John Sampson; Michael Weller
Journal:  JAMA Oncol       Date:  2020-07-01       Impact factor: 31.777
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.